Psoriasis is a chronic systemic inflammatory skin disorder that is strongly associated with metabolic disorders, including obesity, insulin resistance, hypertension, and dyslipidemia. Dyslipidemia causes abnormalities in lipid profiles, such as elevated triglycerides or low density lipoprotein (LDL) levels. Measure maternally expressed gene 3 (MEG3) and microRNA-147b in serum of patients with and without dyslipidemia compared to healthy control. These measurements were compared with clinical characteristics, clinical parameters, and laboratory investigations. Serum expression levels of MEG3 and microRNA-147b, as non-coding RNA biomarkers, were measured across four equally subcategorized groups (patients with and without dyslipidemia (N = 66) and healthy controls with and without dyslipidemia (N = 66) using Polymerase Chain Reaction (PCR). Psoriatic patients exhibited a high significantly body mass index and elevated low-density lipoprotein levels compared with controls (p = 0.038,0.010) respectively, while fasting blood glucose was significantl at p = 0.001. Fasting blood glucose and lipid parameters showed low levels in patients without dyslipidemia and high levels of high-density lipoprotein than those with dyslipidemia. Expression Level of MEG3 was significantly downregulated, whereas microRNA-147b was markedly upregulated in psoriatic patients (p < 0.0001). MEG3 expression was negatively correlated with disease severity indices and lipid levels and inversely correlated with microRNA-147b, which also negatively correlated with disease duration. MEG3 and miR-147b, as non-coding RNAs, may show differential expression among psoriasis patient subgroups and could be associated with disease-related parameters, but their value as markers of disease severity or prognosis remains to be confirmed.
